胰岛素（以及注射的胰岛素）是动脉粥样硬化的主要推手。
原始表述
ويصفه بأنه «المسبب الرئيسي للسمنة» و«من أسباب تصلب الشرايين».
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
胰岛素（以及注射的胰岛素）是动脉粥样硬化的主要推手。
出处
- 来源状态
- 档案网站引语（未注明出处）
- 归属
- Elawady (archive paraphrase; source video not given)
- 出处
- https://eltayebat.com/rule/insulin-injections/
- 归属的不确定性
- The archive attributes this text to Dr. Diaa in its 'د. ضياء يقول' box but gives no video reference. Transcript check (the project's research files, keyword search of 307 archive transcripts): similar_idea_only. A passage links insulin use to clots and narrowing of coronary arteries (5H-C06AT55Q); the term 'atherosclerosis' and the claim that insulin is its 'principal driver' were not checked verbatim. The central sentence of the same archive quote ('insulin is the only hormone causing obesity') is found verbatim (3j32fjfYRbU) but belongs to C-INS-01.
- 所声称的机制
High insulin levels damage arteries.
- 所声称的健康影响
Atherosclerosis, cardiovascular disease
- 涉及人群
People with high insulin / insulin-treated diabetes
- Elawady 设定的地域限制
none found
来源版本存在差异
مش صدفه مش صدفه اللي بياخد انسولين دايما كل سنه يجي له جلطه في الشران بتاع عينيه ولا جلطه في شيران التاجي بالصدفه بالصدفه يضيق عليك وانت بتاخد
It is not a coincidence that whoever takes insulin gets a clot every year in the artery of his eyes or in the coronary arteries; it narrows on you while you are taking [insulin].
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- الذبحة الصدرية ؟! (打开来源)
- 发布日期
- 2025年2月3日
- 时间戳
- 1:13:35 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; YouTube original not checked; wording may contain recognition errors. Similar idea only (clots/narrowing, not 'atherosclerosis' as a term).
科学评估
基本错误 – 该说法的主要部分没有证据支持，或被严重夸大。
证据确定性: 中 – 进一步研究仍可能影响该评估。
1. 说法是什么？
Insulin causes hardening of the arteries.
2. 哪些内容可证实是正确的？
Endogenous hyperinsulinaemia (a marker of insulin resistance) is weakly associated with ischaemic heart disease: odds ratio 1.7 per SD in a Quebec case-control study (A-INS-21); summary RR 1.18 in a meta-analysis that called hyperinsulinaemia a 'weak risk indicator' (A-INS-22). UKPDS 33 itself noted the historical concern that high insulin concentrations may enhance atheroma (A-INS-16).
3. 哪些内容是错误或夸大的？
Association with endogenous hyperinsulinaemia is not proof that therapeutic insulin causes atherosclerosis. In ORIGIN (12,537 people, 6.2 years) insulin glargine had a neutral effect on cardiovascular outcomes (HR 1.02) (A-INS-07). In UKPDS 33 intensive therapy with insulin or sulfonylurea did not increase macrovascular disease (A-INS-16), and 10-year post-trial follow-up showed a 15% reduction in myocardial infarction and 13% in all-cause death in the sulfonylurea-insulin group (I-INS-02). Even in the archive's own observational study of insulin added to metformin, myocardial infarction or stroke (aHR 0.88, 0.59-1.30) and MI/stroke/CV death (aHR 0.98, 0.71-1.34) were not increased; the excess deaths were mainly from cancer and other non-cardiovascular causes (cancer death aHR 1.85), which points to confounding rather than atherogenesis (A-INS-13).
4. 哪些内容仍不明确？
Whether very high doses in severely insulin-resistant patients carry specific vascular risk cannot be separated from confounding in observational data (A-INS-10).
5. 哪些研究支持该说法？
A-INS-21, A-INS-22 (association of endogenous insulin with CHD); I-INS-121 (Mendelian randomisation: genetically higher fasting insulin and CAD, OR 1.79, reflecting insulin resistance).
6. 哪些研究与该说法相矛盾？
A-INS-07, A-INS-16, I-INS-02 (RCTs: no excess cardiovascular events; long-term benefit); I-INS-122 (meta-analysis of 20 RCTs: CV mortality RR 0.99); A-INS-13 (observational: no excess MI/stroke with insulin).
7. 对德国和欧洲而言情况如何？
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
8. 关于埃及的已知情况是什么？
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
9. 合理的实际结论是什么？
血液中胰岛素水平高是胰岛素抵抗的标志，而胰岛素抵抗与心脏病相关。随机对照试验并未显示胰岛素治疗本身会导致心脏病发作。
评估详情
- 证据确定性的依据
Cohort data show a weak association of fasting hyperinsulinaemia with heart disease (A-INS-21, A-INS-22), but this reflects insulin resistance/metabolic syndrome. Large RCTs of insulin therapy (ORIGIN, UKPDS) found no increase in cardiovascular events, and UKPDS long-term follow-up showed fewer myocardial infarctions.
- 来源质量
Archive paraphrase without video reference.
- 地区可推广性
Universal.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
过度解读 – 确有真实的发现，但该说法从中引申出的结论超出了数据所能支持的范围（例如把关联当作因果、把动物数据套用到人身上、把小效应说成大效应）。
研究问题: Does insulin (endogenous or injected) causally drive atherosclerosis?
研究问题详解 (PECO)
- 人群
- People with insulin resistance or insulin-treated diabetes
- 干预或暴露
- Endogenous hyperinsulinaemia; insulin therapy
- 对照
- Lower insulin; non-insulin therapy
- 地域范围
- universal biology
- 结局指标
- Coronary artery disease
- Cardiovascular events and mortality
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Genes for higher insulin levels and heart disease
Mendelian randomisation: genetically higher fasting insulin and CAD.
- 实际结果
- OR 1.79 (1.34-2.40).
- 方法学质量
- moderate (MR; pleiotropy concerns)
- 相关性
- indirect: endogenous insulin/insulin resistance, not insulin therapy
- 局限
- Instruments reflect insulin resistance and adiposity.
Insulin levels and heart disease: pooled analysis
Meta-analysis of cohorts: hyperinsulinaemia and CVD.
- 实际结果
- Summary RR 1.18; 'weak risk indicator'.
- 方法学质量
- moderate
- 相关性
- indirect
- 局限
- Observational.
哪些证据不支持该说法？
Long-term insulin glargine in early diabetes (ORIGIN)
ORIGIN Trial Investigators; Gerstein HC et al.. N Engl J Med 2012 · PMID 22686416 · DOI 10.1056/NEJMoa1203858 随机对照试验全文，含结构化偏倚风险评估ORIGIN RCT: insulin glargine vs standard care.
- 实际结果
- CV outcomes HR 1.02 (0.94-1.11).
- 方法学质量
- high (RCT, 12,537)
- 相关性
- direct for insulin therapy
- 局限
- Early dysglycaemia.
Insulin in type 2 diabetes: what randomised trials show
Erpeldinger S et al.. BMC Endocr Disord 2016 · PMID 27391319 · DOI 10.1186/s12902-016-0120-z Meta分析已核查摘要新增Meta-analysis of 20 RCTs of insulin in T2D.
- 实际结果
- CV mortality RR 0.99 (0.90-1.09).
- 方法学质量
- high
- 相关性
- direct
- 局限
- Trials to 2013.
UKPDS legacy: 10 years after the trial
UKPDS 10-year follow-up.
- 实际结果
- MI -15%, all-cause death -13% in sulfonylurea-insulin group.
- 方法学质量
- high
- 相关性
- direct
- 局限
- Post-trial period.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Endogenous hyperinsulinaemia (insulin resistance) is linked to coronary disease, but insulin therapy does not increase cardiovascular events in RCTs.
为什么有些研究权重更大
RCTs of insulin therapy directly test the claim about injected insulin; MR addresses endogenous insulin with pleiotropy concerns.
因果关系是否已确立？ 有可能，尚未确立 Possible causal role of endogenous hyperinsulinaemia/insulin resistance; no causal effect of therapeutic insulin shown.
仍存在的不确定性
Very high doses in severe insulin resistance.
合理的结论
Mostly false for insulin as 'principal driver' and for insulin therapy.
为什么研究结果看起来互相矛盾？
MR and cohort associations (supporting) concern endogenous insulin as a marker of insulin resistance; RCTs (contradicting) concern injected insulin. They answer different questions.
这是否取决于国家？
- 一般生物学效应
- Insulin physiology, autoimmune type 1 diabetes and ketoacidosis are universal human biology.
- 饮食习惯
- Egyptian and European diets differ, but no dietary pattern replaces insulin in insulin-deficient diabetes.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant.
- 本国生产条件
- Not relevant.
- 法律规则
- Insulin is an essential medicine (WHO list) in Egypt and the EU; prescription rules not relevant to the scientific question.
- 实际监测数据
- Egyptian/Middle Eastern data show severe DKA is common at presentation in children (I-INS-115, I-INS-114); no data on outcomes among Tayebat followers.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- CI log-symmetry and implied SE – Symmetric; SE(log OR) about 0.149 已重新计算
- Compatibility with harm – CV mortality CI 0.90-1.09 excludes large harm 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Cardiovascular events with insulin therapy
- 起始等级
- 高（随机试验）
- 降级理由
- indirectness (mostly T2D populations, early to moderate disease)
- 结果
- 中
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ADA: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (I-ODD-16) (2026) · 原始文献
'Insulin treatment is essential for individuals with type 1 diabetes'; insulin to be considered in T2D when A1C >10%, glucose >=300 mg/dL or catabolic features (as recorded for I-ODD-16). - ADA: 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026) · 原始文献
Rec 10.1: measure blood pressure at every routine visit or at least every 6 months; rec 10.2 (A): home BP monitoring for people with hypertension and diabetes.
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| PubMed | 2026年10月26日 | "mendelian randomization" AND ("fasting insulin" OR hyperinsulinemia OR "insulin secretion") AND ("coronary artery disease" OR "coronary heart disease" OR atherosclerosis) | 支持性证据 | 66 | |
| PubMed | 2026年10月26日 | hyperinsulinemia AND atherosclerosis AND (causal OR "mendelian randomization") AND human | 支持性证据 | 4386 | |
| Europe PMC | 2026年10月26日 | (TITLE:"hyperinsulinemia" OR TITLE:"hyperinsulinaemia") AND (TITLE:"atherosclerosis" OR TITLE:"coronary") AND (cohort OR "mendelian") | 支持性证据 | 9 | |
| PubMed | 2026年10月26日 | (insulin therapy OR "insulin treatment") AND "type 2 diabetes" AND (cardiovascular OR mortality) AND meta-analysis[pt] AND (randomized OR randomised) | 反对性证据 | 210 | |
| Europe PMC | 2026年10月26日 | (TITLE:"insulin therapy" OR TITLE:"insulin treatment") AND (TITLE:"atherosclerosis" OR TITLE:"cardiovascular") AND (randomized OR randomised) AND "type 2 diabetes" | 反对性证据 | 25 | |
| PubMed | 2026年10月26日 | Erpeldinger S[au] AND insulin | 反对性证据 | 2 |
核查深度如何？
9 项相关研究：2 项核查了全文（其中 2 项进行了结构化偏倚风险评估），7 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
通俗解释
因胰岛素抵抗而自身分泌大量胰岛素的人，患心脏病的比例略高。但当医生在大型随机对照试验中检验胰岛素治疗时，它并没有使心脏病发作或卒中增加。在一项长期的英国研究中，早期接受胰岛素或口服药治疗的人，多年后心脏病发作反而更少。
与该说法相关的研究
支持该说法的研究 (3)
-
High natural insulin and heart disease
Després JP et al.. N Engl J Med 1996 · PMID 8596596 · DOI 10.1056/NEJM199604113341504病例对照研究被 Tayebat 档案网站引用已核查摘要Men with higher fasting insulin had more heart disease.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Is fasting hyperinsulinaemia an independent risk factor for IHD?
- 研究是如何开展的？
Nested case-control within prospective cohort (Quebec)
- 研究了多少人、动物或样本？
2,103 men; 91 cases, 105 controls; Non-diabetic men 45-76
- 实际发现了什么？
OR 1.7 per SD.
- 观察到的效应有多大？
OR 1.6-1.7
- 研究结果对日常生活意味着什么？
Insulin resistance is a heart risk marker.
- 该研究有哪些局限？
Small number of cases; Men only; Endogenous insulin, not therapy
- 它对 Elawady 的具体说法说明了什么？
Association for C-INS-03.
- 研究结果是否适用于德国和欧洲？
Canadian men.
- 从该研究中明确不能得出什么结论？
That insulin injections cause heart disease.
-
Insulin levels and heart disease: pooled analysis
Ruige JB et al.. Circulation 1998 · PMID 9529268 · DOI 10.1161/01.cir.97.10.996Meta分析被 Tayebat 档案网站引用已核查摘要Higher insulin was only weakly linked to heart disease (18% higher risk).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Strength of relation between hyperinsulinaemia and CVD
- 研究是如何开展的？
Meta-analysis of prospective cohorts and nested case-control studies
- 研究了多少人、动物或样本？
12 studies; General population cohorts
- 实际发现了什么？
RR 1.18.
- 观察到的效应有多大？
RR 1.18 (1.08-1.29)
- 研究结果对日常生活意味着什么？
Weak signal.
- 该研究有哪些局限？
Old assays; Heterogeneity
- 它对 Elawady 的具体说法说明了什么？
Weak association for C-INS-03.
- 研究结果是否适用于德国和欧洲？
Includes Dutch data.
- 从该研究中明确不能得出什么结论？
Causation; anything about insulin therapy.
-
Genes for higher insulin levels and heart disease
Huang X et al.. BMC Med 2025 · PMID 40442727 · DOI 10.1186/s12916-025-04127-6其他独立交叉核查已核查摘要★ 关键研究People genetically inclined to higher fasting insulin had a higher risk of coronary artery disease.
Genetically higher fasting insulin linked to CAD (OR 1.79); endogenous, not therapeutic insulin.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test whether higher fasting insulin causes coronary disease.
- 研究是如何开展的？
Mendelian randomisation.
- 研究了多少人、动物或样本？
Large genetic datasets.
- 实际发现了什么？
OR 1.79 for CAD.
- 观察到的效应有多大？
OR 1.79 (1.34-2.40).
- 研究结果对日常生活意味着什么？
Insulin resistance with high natural insulin is bad for arteries.
- 该研究有哪些局限？
Instruments reflect insulin resistance; no data on insulin therapy.
- 它对 Elawady 的具体说法说明了什么？
Supports the kernel about natural high insulin, not about insulin injections.
- 研究结果是否适用于德国和欧洲？
Mostly European data.
- 从该研究中明确不能得出什么结论？
Cannot say insulin treatment causes atherosclerosis.
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (5)
-
Long-term insulin glargine in early diabetes (ORIGIN)
ORIGIN Trial Investigators; Gerstein HC et al.. N Engl J Med 2012 · PMID 22686416 · DOI 10.1056/NEJMoa1203858随机对照试验被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究Over six years insulin did not change heart attacks, strokes or cancers, but caused more low-sugar episodes and 2 kg weight difference.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Does basal insulin glargine targeting normal fasting glucose reduce CV events in dysglycaemia?
- 研究是如何开展的？
International multicentre RCT, 2x2 factorial (ORIGIN)
- 研究了多少人、动物或样本？
12,537; CV risk factors plus IFG, IGT or type 2 diabetes; mean age 63.5
- 实际发现了什么？
Neutral CV and cancer outcomes; more hypoglycaemia, slight weight gain.
- 观察到的效应有多大？
HR 1.02 CV; HR 1.00 cancer
- 研究结果对日常生活意味着什么？
Insulin itself did not cause heart disease or cancer in this large trial.
- 该研究有哪些局限？
Open-label; funded by the glargine manufacturer; early-diabetes population on moderate doses (~28 units/day for 70 kg).
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- 从该研究中明确不能得出什么结论？
Safety in very high-dose, late-stage type 2 diabetes.
-
UKPDS: tablets or insulin for new type 2 diabetes
UKPDS Group. Lancet 1998 · PMID 9742976随机对照试验被 Tayebat 档案网站引用已核查摘要★ 关键研究Better sugar control with tablets or insulin cut eye/kidney complications by a quarter; insulin caused more weight gain and low-sugar episodes.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Intensive control with sulfonylurea or insulin vs diet on complications
- 研究是如何开展的？
Multicentre RCT (UKPDS 33)
- 研究了多少人、动物或样本？
3,867; Newly diagnosed type 2 diabetes, median age 54
- 实际发现了什么？
Microvascular -25%; more hypoglycaemia and weight gain with insulin.
- 观察到的效应有多大？
RR reduction 25% microvascular
- 研究结果对日常生活意味着什么？
Insulin helps prevent complications but has side effects.
- 该研究有哪些局限？
Open-label; Older drug regimens
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
UK; directly relevant.
- 从该研究中明确不能得出什么结论？
That insulin is harmful overall.
-
UKPDS legacy: 10 years after the trial
Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470随机对照试验独立交叉核查已核查摘要★ 关键研究People treated intensively early with sulfonylureas or insulin had 15% fewer heart attacks and 13% fewer deaths years later.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Do UKPDS benefits persist and do macrovascular effects emerge?
- 研究是如何开展的？
Post-trial monitoring of an RCT (UKPDS 80)
- 研究了多少人、动物或样本？
4,209 randomised; 3,277 monitored; Newly diagnosed type 2 diabetes from UKPDS
- 实际发现了什么？
Legacy reductions in MI and death.
- 观察到的效应有多大？
Death -13% (SU/insulin), -27% (metformin)
- 研究结果对日常生活意味着什么？
Early good control pays off for decades.
- 该研究有哪些局限？
Post-trial therapy not controlled; Questionnaire follow-up
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
UK; directly relevant.
- 从该研究中明确不能得出什么结论？
Effects of extreme targets in late disease.
-
Second drug after metformin: insulin or sulfonylurea
Roumie CL et al.. JAMA 2014 · PMID 24915260 · DOI 10.1001/jama.2014.4312队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估★ 关键研究Veterans who added insulin died more often than those who added a sulfonylurea, but heart attacks and strokes were not more frequent.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Adding insulin vs sulfonylurea to metformin: AMI, stroke, death
- 研究是如何开展的？
Retrospective cohort with propensity matching and marginal structural models (VHA, Medicare, NDI)
- 研究了多少人、动物或样本？
178,341 (matched 2,436 insulin vs 12,180 SU); Veterans initially treated with metformin
- 实际发现了什么？
Composite aHR 1.30; death aHR 1.44; CV events not increased.
- 观察到的效应有多大？
aHR 1.30 (1.07-1.58)
- 研究结果对日常生活意味着什么？
Possibly reflects sicker patients getting insulin.
- 该研究有哪些局限？
Residual confounding (sicker patients get insulin); median follow-up about 1 year; mostly male veterans; extra deaths were mainly from cancer and other non-heart causes.
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
US veterans.
- 从该研究中明确不能得出什么结论？
That insulin causes death.
-
Insulin in type 2 diabetes: what randomised trials show
Erpeldinger S et al.. BMC Endocr Disord 2016 · PMID 27391319 · DOI 10.1186/s12902-016-0120-zMeta分析独立交叉核查已核查摘要★ 关键研究In 20 trials with 18,599 people, insulin did not change the risk of death but caused more severe low blood sugar.
No increase in CV mortality with insulin.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Summarise RCTs of insulin in T2D.
- 研究是如何开展的？
Meta-analysis of 20 RCTs.
- 研究了多少人、动物或样本？
18,599 patients.
- 实际发现了什么？
Mortality unchanged; severe hypoglycaemia +70%.
- 观察到的效应有多大？
RR 0.99 death; 1.70 severe hypoglycaemia.
- 研究结果对日常生活意味着什么？
Insulin does not kill, but low sugar is a real risk; use it carefully.
- 该研究有哪些局限？
Older trials; heterogeneity.
- 它对 Elawady 的具体说法说明了什么？
Refutes 'insulin doubles mortality'; supports caution.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot address insulin in type 1 diabetes, where it is essential.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (1)
-
Higher insulin doses and outcomes
Holden SE et al.. Diabetes Obes Metab 2015 · PMID 25399739 · DOI 10.1111/dom.12412队列研究被 Tayebat 档案网站引用已核查摘要★ 关键研究People on higher insulin doses died more often, but higher doses are needed by sicker, more insulin-resistant people.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Association of insulin dose with mortality, MACE, cancer
- 研究是如何开展的？
Retrospective cohort, UK CPRD, time-dependent dose exposure
- 研究了多少人、动物或样本？
6,484; Type 2 diabetes progressing to insulin monotherapy from 2000
- 实际发现了什么？
Dose-associated increases in death, MACE, cancer.
- 观察到的效应有多大？
aHR 1.54 per IU/kg/day
- 研究结果对日常生活意味着什么？
High doses mark severe disease; cause unclear.
- 该研究有哪些局限？
Dose reflects insulin resistance and illness; Reverse causation; Residual confounding
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
UK data.
- 从该研究中明确不能得出什么结论？
That lowering doses would save lives.
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
埃及
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
在我的国家适用什么？
一般科学评估
基本错误 体内自身分泌的胰岛素水平高是一个较弱的风险标志，但胰岛素治疗并未被证明会导致动脉粥样硬化。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Hyperinsulinemia as an independent risk factor for ischemic heart disease.. Després JP et al.. N Engl J Med 1996 · PMID 8596596 · DOI 10.1056/NEJM199604113341504
- Insulin and risk of cardiovascular disease: a meta-analysis.. Ruige JB et al.. Circulation 1998 · PMID 9529268 · DOI 10.1161/01.cir.97.10.996
- Exploring the pathways linking fasting insulin to coronary artery disease: a proteome-wide Mendelian randomization study.. Huang X et al.. BMC Med 2025 · PMID 40442727 · DOI 10.1186/s12916-025-04127-6
- Basal insulin and cardiovascular and other outcomes in dysglycemia.. ORIGIN Trial Investigators; Gerstein HC et al.. N Engl J Med 2012 · PMID 22686416 · DOI 10.1056/NEJMoa1203858
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.. UKPDS Group. Lancet 1998 · PMID 9742976
- 10-year follow-up of intensive glucose control in type 2 diabetes.. Holman RR et al.. N Engl J Med 2008 · PMID 18784090 · DOI 10.1056/NEJMoa0806470
- Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes.. Roumie CL et al.. JAMA 2014 · PMID 24915260 · DOI 10.1001/jama.2014.4312
- Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials.. Erpeldinger S et al.. BMC Endocr Disord 2016 · PMID 27391319 · DOI 10.1186/s12902-016-0120-z
- Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.. Holden SE et al.. Diabetes Obes Metab 2015 · PMID 25399739 · DOI 10.1111/dom.12412